Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 33,106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms

NCT02497560
View directory record Official record
Conditions
Menopause
Interventions
proprietary formula
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Colorado Springs, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

NCT04147260
View directory record Official record
Conditions
Healthy
Interventions
BI 730357, Placebo to match BI 730357, Ciprofloxacin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

NCT03289520
View directory record Official record
Conditions
Kidney Failure, Hemodialysis Fistula Thrombosis
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome

NCT00587860
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
St. John's wort, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

NCT00993824
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
colesevelam HCl, placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 28, 2026, 1:34 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

NCT07527923
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis
Interventions
REGN20423, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • West Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 1:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

NCT00801723
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX 6 mg Tablet, Placebo Tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
53
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

NCT00163059
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
NMDA Antagonist, CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Nalmefene Smoking Cessation Study

NCT00202696
View directory record Official record
Conditions
Smoking Cessation
Interventions
nalmefene, Placebo
Drug · Other
Lead sponsor
Somaxon Pharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain

NCT03240146
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pulsed Shortwave Therapy
Device
Lead sponsor
BioElectronics Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Athens, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

NCT02629861
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
178
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 28, 2026, 1:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 28, 2026, 1:34 AM EDT
Not yet recruiting Phase 2 Interventional

T4/T3 Therapy in Hypothyroidism

NCT07424183
View directory record Official record
Conditions
Hypothyroidism Primary
Interventions
Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 1:34 AM EDT
Not yet recruiting Phase 2 Interventional

Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis

NCT06961383
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
NG01 - Autologous bone marrow derived human stromal cells, Sodium Chloride 0.9%
Biological · Other
Lead sponsor
NeuroGenesis Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Satiety and Alcohol Challenge

NCT06576674
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Dietary Fiber + Green Tea Extract, Alcohol, Aspartame Placebo Supplement
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT05496374
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Interventions
Placebo, SPR720 500 mg, SPR720 1000 mg
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

NCT03015610
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux
Interventions
commercially available lansoprazole, matched placebo
Drug
Lead sponsor
Jason Lang, M.D., M.P.H.
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

NCT05925920
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
ENT-03, Placebo
Drug
Lead sponsor
Metabolics Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 28, 2026, 1:34 AM EDT